Athenex
Conventus Building
1001 Main Street, Suite 600
Buffalo
New York
14203
United States
Tel: 716-427-2950
Website: http://www.athenex.com/
118 articles with Athenex
-
Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program
6/4/2021
Data from oral docetaxel phase I pharmacokinetic study shows oral administration can achieve exposure comparable to IV docetaxel
-
Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or ScalpEuropean Commission Decision Anticipated by July 2021
5/21/2021
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its partner, Almirall (Almirall, S.A., BME: ALM), has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the regulatory approval of Klisyri®
-
Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKT Cells in Neuroblastoma at ASGCT Annual Meeting
5/17/2021
Athenex, Inc. announced that investigators from Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine presented new clinical data from the ongoing GINAKIT2 phase 1 study of Athenex’s cell therapy candidate KUR-501 targeting GD2 in neuroblastoma at the American Society of Gene & Cell Therapy 24th Annual Meeting on Friday, May 14, at 11 am ET.
-
Two new notable biotech/biopharma acquisitions were reported this week: Athenex has acquired Kuur Therapeutics, while Altasciences has acquired preclinical CRO Calvert Laboratories.
-
Athenex Provides First Quarter 2021 Corporate and Financial Update
5/6/2021
Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, provided a corporate and financial update for the first quarter ended March 31, 2021.
-
Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform
5/4/2021
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, led by its Orascovery platform, today announced that it has acquired Kuur Therapeutics, Inc.
-
Athenex to Provide Corporate and Financial Update for the First Quarter 2021 on May 6, 2021
4/27/2021
Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that the Company will provide a corporate and financial update for the first quarter 2021, on Thursday, May 6, 2021, before the market opens.
-
Athenex Receives FDA Complete Response Letter for Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer
3/1/2021
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the company’s New Drug Application (NDA)
-
Athenex Provides Fourth Quarter and Full Year 2020 Corporate and Financial Update
3/1/2021
Receipt of Complete Response Letter from the FDA for Oral Paclitaxel Plus Encequidar Klisyri® (tirbanibulin) received FDA approval and launched commercially on February 18, 2021 The New England Journal of Medicine published Phase III trial data on the efficacy and safety of Klisyri® Product sales in 4Q20 grew 54.4% Y/Y to $21.8 million 2021 product sales (excluding proprietary products) expected to be in line with 2020 Management to host conference call and webcast today at 8:00 a.m. ET
-
Athenex to Provide a Corporate and Financial Update for the Fourth Quarter and Full Year 2020 on March 1, 2021
2/22/2021
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the fourth quarter and full year 2020 on Monday, March 1, 2021, before the market opens.
-
Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin
2/18/2021
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that today marks the U.S. launch of Klisyri® (tirbanibulin) in the United States, led by the Company’s partner Almirall.
-
Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy and Safety of Klisyri® (tirbanibulin)
2/11/2021
The New England Journal of Medicine published the Phase III trial results on Klisyri®, an anti-proliferative agent that inhibits tubulin polymerization and Src kinase signaling, for the topical treatment of actinic keratosis (AK) of the face or scalp Klisyri®, developed by Athenex, received FDA approval in December 2020
-
CEO Dr. Johnson Lau Recuperating from COVID at Home
1/25/2021
Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its CEO and Board Chairman, Dr. Johnson Lau, has been discharged from the hospital and is doing well recuperating at home.
-
Athenex CEO Dr. Johnson Lau Contracts COVID-19
1/8/2021
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its CEO and Board Chairman, Dr. Johnson Lau, has contracted COVID-19. Dr. Lau is receiving oral and intravenous treatment at a local hospital, and his condition is currently stable. Dr. Lau is communicating with senior management and
-
The U.S. Food and Drug Administration (FDA) had several approvals this week. Read on to see what the regulatory agency gave the go-ahead to.
-
Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp
12/15/2020
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug Administration (FDA) has approved Klisyri® (tirbanibulin) for the topical treatment of actinic keratosis (AK) on the face or scalp.
-
Athenex Presents Updated Phase 3 Data on Survival and Tolerability Associated with Oral Paclitaxel and Encequidar in Patients with Metastatic Breast Cancer
12/9/2020
Data presented at SABCS indicates benefits of oral paclitaxel and encequidar (oral paclitaxel) versus IV paclitaxel (IV P ) on Progression-Free Survival (PFS) and on Overall Survival (OS), which suppor ts superiority o n the primary endpoint Overall Response Rate (ORR) . In the intent - to - treat ( I TT) population, oral paclitaxel showed a benefit on PFS versus IVP , and showed a trend favoring oral paclitaxel on OS versus IVP.
-
Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute Cyclophosphamide
12/2/2020
Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that its subsidiary, Athenex Pharmaceutical Division (APD), has launched Liquid, Ready-To-Dilute Cyclophosphamide
-
Athenex Announces Data on Oral Paclitaxel and Encequidar to be Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)
11/17/2020
Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that oral paclitaxel and encequidar (“oral paclitaxel”) data will be presen
-
Athenex, Inc. Reports Third Quarter Ended September 30, 2020 Financial Results and Provides Corporate Update
11/5/2020
FDA accepted and granted priority review of NDA for Oral Paclitaxel in metastatic breast cancer PDUFA dates for tirbanibulin ointment and Oral Paclitaxel set for December 30, 2020 and February 28, 2021, respectively Four abstracts featuring Oral Paclitaxel accepted for presentation at San Antonio Breast Cancer Virtual Symposium Product sales in Q3 2020 were $24.8 million, up 29% y/y -- raising full year 2020 guidance to low 20% growth